
==== Front
Cureus
Cureus
2168-8184
Cureus
2168-8184
Cureus Palo Alto (CA)

10.7759/cureus.66137
Infectious Disease
Pulmonology
Pulmonary Nocardiosis Caused by Nocardia sputorum Identified via 16S rRNA Gene Sequencing: A Case Report
Muacevic Alexander
Adler John R
Irifune Satoshi 12
Ide Shotaro 34
Koga Satoru 2
Mine Keisuke 2
Sugasaki Nanae 2
Kosai Kosuke 5
Fukuda Minoru 6
Yanagihara Katsunori 5
Mukae Hiroshi 14
1 Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JPN
2 Department of Respiratory Medicine, Nagasaki Prefecture Shimabara Hospital, Nagasaki, JPN
3 Infectious Diseases Experts Training Center, Nagasaki University Hospital, Nagasaki, JPN
4 Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, JPN
5 Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, JPN
6 Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Isahaya Hospital, Nagasaki, JPN
Shotaro Ide str-ide@nagasaki-u.ac.jp
4 8 2024
8 2024
16 8 e661374 8 2024
Copyright © 2024, Irifune et al.
2024
Irifune et al.
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article is available from https://www.cureus.com/articles/279916-pulmonary-nocardiosis-caused-by-nocardia-sputorum-identified-via-16s-rrna-gene-sequencing-a-case-report
Nocardia sputorum, a novel Nocardia species discovered in Japan in 2023, has not been reported to infect humans. Here, we report a case of pulmonary nocardiosis in a 70-year-old immunocompetent woman infected with N. sputorum. The patient presented to the hospital with a chief complaint of weight loss. She worked at a fruit sorting facility where she was exposed to dust. Chest computed tomography revealed a single cavity and diffuse nodular opacities in both lungs. Nocardia species was isolated from tracheal sputum and bronchial lavage fluid and identified as N. sputorum via 16S rRNA gene sequencing. The patient was treated with oral sulfamethoxazole and trimethoprim but developed oral mucositis on the 12th day of treatment. Consequently, minocycline was prescribed, and the patient's condition improved after a six-month course of treatment. To our knowledge, this is the first reported case of pulmonary nocardiosis caused by N. sputorum in humans. Accurate species identification and antimicrobial susceptibility tests will be necessary to prescribe appropriate treatment for Nocardia infections.

anaerobe
anaerobic bacteria
16s rrna gene
nocardia sputorum
nocardiosis
pulmonary infection
==== Body
pmcIntroduction

Nocardia are gram-positive to gram-variable, aerobic, and acid-fast filamentous branching bacteria belonging to the family Nocardiaceae. They are ubiquitous in various environments, such as soil, vegetables, other plants, and water. Nocardia causes acute or chronic infections in humans affecting the lungs, central nervous system, and skin [1]. These infections are typically opportunistic; however, it is estimated that one-third of the affected individuals are immunocompetent [1,2]. Novel species of the genus Nocardia have been discovered via molecular biology methods; more than 100 species have been identified in total, approximately half of which are pathogenic to humans [3,4]. Nocardia sputorum is a novel species isolated from clinical specimens in Japan in 2023; however, its pathogenicity in humans has not been reported [5]. To the best of our knowledge, we report the first case of pulmonary nocardiosis caused by N. sputorum in an immunocompetent patient.

Case presentation

A 70-year-old woman presented to our hospital with a weight loss of 10 kg over the past six months without any other symptoms, including fever, cough, sputum production, or shortness of breath. The patient was employed at a fruit sorting facility, where she was frequently exposed to dust without wearing a protective mask. Physical examination revealed clear breath sounds, absence of skin rash, and absence of neurological signs. Blood tests showed a white blood cell count of 8,100 cells/µL, a neutrophil count of 6,100 cells/µL, a lymphocyte count of 1,400 cells/µL, a C-reactive protein level of 3.23 mg/dL, negative human immunodeficiency virus antigen/antibody test results, and negative blood culture results. Chest radiography revealed diffuse nodular opacities in both lungs (Figure 1A), and chest computed tomography (CT) revealed multiple diffuse centrilobular nodules in both lungs along with a small cavity (Figure 1B).

Figure 1 Chest radiograph and computed tomography

A: Chest radiograph shows diffuse nodular opacities; B: Chest computed tomography shows a cavitary lesion (white arrows) in the left upper lobe and bilateral centrilobular bronchiolitis (yellow circles).

The presence of cavities led to the differential diagnosis of pulmonary tuberculosis and nontuberculous mycobacteriosis; however, sputum cultures did not contain mycobacteria, bacteria, or fungi. Bronchoscopy was performed, followed by sputum collection from the trachea and bronchial lavage. Gram and Kinyoun staining for these samples revealed the presence of a gram-positive, weak acid-fast, and filament-like bacterium in smears and cultures (Figure 2), which was identified as a Nocardia sp. via matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).

Figure 2 Gram staining for isolates from tracheal sputum and bronchoalveolar fluid show a gram-positive and filament-like bacterium

Subsequently, further testing was performed using 16S rRNA gene sequencing at the Nagasaki University Hospital, Nagasaki, Japan. The 16S rRNA gene was amplified using the primers 8UA (5′-AGAGAGTTTGATCMTGGCTCAG-3′) and 1485B (5́’-ACGGGCGGTGTGTRC-3′) [6]. The nucleotide sequence was determined and searched against the BLAST database (https://blast.ncbi.nlm.nih.gov/Blast.cgi), and it showed 100% nucleotide identity (1,243/1,243) with N. sputorum [7]. Brain CT and contrast-enhanced magnetic resonance imaging showed no evidence of brain abscess; thus, the patient was diagnosed with pulmonary nocardiosis. The patient was treated with oral sulfamethoxazole and trimethoprim (ST) based on antimicrobial susceptibility testing results (Table 1) [8].

Table 1 Antimicrobial susceptibility testing for Nocardia sputorum

MIC: minimum inhibitory concentration; S: sensitive; I: intermediate resistance; R: resistance

Antimicrobial agent	MIC (µg/mL) for category [8]	Present case	Hamada et al. [5]  (2 strains)	
S	I	R	
Amikacin	≤8	-	≥16	≤4	S	S	
Amoxicillin-clavulanic acid	≤8/4	16/8	≥32/16	≤4	S	S	
Ceftriaxone	≤8	16–32	≥64	8	S	-	
Ciprofloxacin	≤1	2	≥4	-	-	R	
Clarithromycin	≤2	4	≥8	≤1	S	R	
Imipenem	≤4	8	≥16	>16	R	R	
Linezolid	≤8	-	-	≤2	S	S	
Minocycline	≤1	2–4	≥8	1	S	-	
Moxifloxacin	≤1	2	≥4	≤0.5	S	S	
Trimethoprim-Sulfamethoxazole	≤2/38	-	≥4/76	≤0.5	S	S	
Tobramycin	≤4	8	≥16	≤1	S	S	
Cefotaxime	≤8	16–32	≥64	≤1	S	-	

However, on the 12th day of treatment, the patient exhibited grade 3 oral mucositis based on the Common Terminology Criteria for Adverse Events version 5.0. Consequently, ST treatment was discontinued, and minocycline (MINO) was prescribed. Following a six-month course of treatment, weight loss improved in the patient, and chest CT revealed improvement in centrilobular nodules in both lungs (Figure 3A, 3B). The patient did not exhibit any recurrence at the three-month follow-up after treatment termination.

Figure 3 Chest radiograph and computed tomography after six months of treatment

A: Chest radiograph shows improvement in diffuse nodular opacities; B: Chest computed tomography shows improvement in cavitary lesion (white arrows) and centrilobular nodules (yellow circles).

Discussion

To the best of our knowledge, this case report describes the first documented infection of N. sputorum in humans. Nocardia are gram-positive aerobic bacilli found in soil, plants, and water. Molecular biological tools have led to the discovery of novel species within the genus Nocardia; 130 species have been validly published at the time of this study [9,10]. The prevalence of Nocardia species varies with geographical location. Nocardia nova complex was the most commonly isolated clinical strain between 1995 and 2004 in the United States, comprising 28% of the total, followed by Nocardia brasiliensis and Nocardia farcinica, which accounted for 14% of the isolates [11]. Nocardia cyriacigeorgica and N. nova complex were the dominant clinical isolates between 2020 and 2021 in Western Australia, representing 27% and 20% of the total, respectively; however, there were regional differences [12]. Takamatsu et al. (2022) reported that N. farcinica was the most commonly identified clinical strain in Japan between 2010 and 2017, accounting for 24.9% of the isolates, followed by N. nova complex (19.2%) and Nocardia abscessus complex (18.6%) [13]. From 2006 to 2021, 48 novel Nocardia species were identified, 17 of which were obtained from human specimens [4]. Furthermore, pathogenic Nocardia species that infect humans have been reported in recent years [14-17].

N. sputorum is a recently discovered species isolated from a clinical specimen, and it was first reported by Hamada et al. (2023) in Japan in 2023 [5]. N. sputorum exhibited high similarity to Nocardia beijingensis (99.6%), Nocardia sputi (99.6%), Nocardia niwae (99.3%), and Nocardia araoensis (99.3%) based on 16S rRNA gene sequencing. However, the phenotypic characteristics, DNA-DNA hybridization analysis, and genome sequencing distinguished it as a novel species within the genus Nocardia, and this has been validly published under the International Code of Nomenclature of Prokaryotes [9,10]. Two strains were previously isolated from the sputum and a clinical sample of unknown origin; however, their pathogenicity in humans has not yet been reported. According to us, this case report is the first to report the pathogenicity of N. sputorum in humans based on a pulmonary infection. MALDI-TOF MS and 16S rRNA gene sequencing have been used to identify Nocardia; however, the use of MALDI-TOF MS can lead to misidentification [18]. N. sputorum may be misidentified as other Nocardia species such as N. beijingensis, N. sputi, N. niwae, and N. araoensis. In contrast, 16S rRNA gene sequencing is useful for accurate identification of Nocardia species. The Nocardia species isolated from our patient was unidentifiable via MALDI-TOF MS and required identification using 16S rRNA gene sequencing.

Although pulmonary nocardiosis is relatively more common in immunocompromised patients, it also affects healthy individuals without immunodeficiency [1,2]. The present case reported pulmonary infection in an immunocompetent host, and radiological findings revealed centrilobular nodular opacities and cavitary lesions. The possible source of infection was considered to be contact with contaminated vegetables in the selection area and inhalation of soil dust. However, the isolation of N. sputorum from soil has not been reported.

No standard treatment regimen has been established for nocardiosis, and antibiotics and treatment durations are customized according to the infection site, underlying disease, severity, and antimicrobial susceptibility testing [1,4]. Several Nocardia species are susceptible to ST, which is used as a first-line drug [13,19]. However, certain Nocardia species are resistant to ST; therefore, accurate species identification and antimicrobial susceptibility testing are necessary. The strain isolated from this patient and the two strains reported by Hamada et al. (2023) were found to be susceptible to ST, amoxicillin-clavulanic acid, MINO, and moxifloxacin while displaying resistance to imipenem. Conversely, our strains were susceptible to clarithromycin, with the latter two strains exhibiting resistance. N. beijingensis, which N. sputorum was likely misidentified, is included in N. abscessus complex, and the susceptibility rates to ST, amoxicillin-clavulanic acid, MINO, moxifloxacin, clarithromycin, and imipenem were reported as 98.7-100%, 26.3%, 67-98.7%, 22%, 17-51.3%, and 72-88.2%, respectively [19,20]. These differences highlight the importance of species identification. The patient was initially administered ST, which was discontinued due to grade 3 mucositis. Since no bacteria other than N. sputorum were detected in this patient and there was no evidence of central nervous system infection, treatment was switched to MINO based on antimicrobial susceptibility testing and antimicrobial spectrum, and a favorable response was observed.

To the best of our knowledge, this is the first report of pulmonary nocardiosis caused by N. sputorum, a novel species reported in 2023, which may have been previously misidentified as N. beijingensis or N. sputi. Additional cases need to be evaluated to determine the clinical features of N. sputorum infection and appropriate antimicrobial therapy.

Conclusions

To the best of our knowledge, this report presents the first documented case of human infection caused by Nocardia sputorum, a novel species of Nocardia discovered in Japan in 2023. Differences in the clinical course and characteristics of nocardiosis depending on the species are unknown. In contrast, Nocardia species exhibit a variety of antimicrobial susceptibilities. This case emphasizes the significance of precise species identification and antimicrobial susceptibility testing for effective treatment of Nocardia infections. Further cases need to be assessed to determine the clinical characteristics of N. sputorum infection and the appropriate antimicrobial therapy.

All authors meet the ICMJE authorship criteria. S. Irifune served as the primary care physician for the case and collected the data and wrote the manuscript. S. Ide oversaw the care of the patient, collected the data, and wrote the manuscript. SK, KM, NS, and MF participated in discussions as a medical team regarding the patient's treatment plan and collected the data. KK and KY provided microbiological advice and supervised identification methods and results. HM provided therapeutic and conceptual advice and supervised the treatment and manuscript. We would like to thank the microbiology laboratory staff at Nagasaki Prefecture Shimabara Hospital and the respiratory medicine and microbiology laboratory staff at Nagasaki University Hospital. We would also like to thank Editage (www.editage.jp) for English language editing.

Disclosures

Author Contributions

Human subjects: Consent was obtained or waived by all participants in this study.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Concept and design:  Shotaro Ide, Satoshi Irifune, Satoru Koga, Katsunori Yanagihara

Acquisition, analysis, or interpretation of data:  Shotaro Ide, Hiroshi Mukae, Satoshi Irifune, Keisuke Mine, Nanae Sugasaki, Kosuke Kosai, Minoru Fukuda

Drafting of the manuscript:  Shotaro Ide, Satoshi Irifune

Critical review of the manuscript for important intellectual content:  Shotaro Ide, Hiroshi Mukae, Satoshi Irifune, Satoru Koga, Keisuke Mine, Nanae Sugasaki, Kosuke Kosai, Minoru Fukuda, Katsunori Yanagihara

Supervision:  Shotaro Ide, Hiroshi Mukae
==== Refs
References

1 Nocardiosis: updates and clinical overview Mayo Clin Proc Wilson JW 403 407 87 2012 22469352
2 Nocardia species: host-parasite relationships Clin Microbiol Rev Beaman BL Beaman L 213 264 7 1994 8055469
3 The complexities of Nocardia taxonomy and identification J Clin Microbiol Conville PS Brown-Elliott BA Smith T Zelazny AM 56 2018
4 Updated review on Nocardia species: 2006-2021 Clin Microbiol Rev Traxler RM Bell ME Lasker B Headd B Shieh WJ McQuiston JR 0 35 2022
5 Nocardia sputorum sp. nov., an actinobacterium isolated from clinical specimens in Japan Int J Syst Evol Microbiol Hamada M Enomoto N Yamashita T 73 2023
6 Mycobacterium kumamotonense Sp. Nov. recovered from clinical specimen and the first isolation report of Mycobacterium arupense in Japan: Novel slowly growing, nonchromogenic clinical isolates related to Mycobacterium terrae complex Microbiol Immunol Masaki T Ohkusu K Hata H 889 897 50 2006 17116985
7 Basic Local Alignment Search Tool 4 2024 https://blast.ncbi.nlm.nih.gov/Blast.cgi
8 Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes, 2nd edition Wayne Woods GL Brown-Elliott BA Conville PS Wayne Clinical and Laboratory Standards Institute 2011 https://www.ncbi.nlm.nih.gov/books/NBK544374/
9 List of Prokaryotic names with Standing in Nomenclature - Genus Nocardia 4 2024 https://lpsn.dsmz.de/genus/nocardia
10 List of Prokaryotic names with Standing in Nomenclature (LPSN) moves to the DSMZ Int J Syst Evol Microbiol Parte AC Sardà Carbasse J Meier-Kolthoff JP Reimer LC Göker M 5607 5612 70 2020 32701423
11 Antimicrobial-resistant nocardia isolates, United States, 1995-2004 Clin Infect Dis Uhde KB Pathak S McCullum I Jr 1445 1448 51 2010 21058914
12 Nocardia species distribution and antimicrobial susceptibility within Australia Intern Med J O'Brien A Hart J Higgins A 613 619 54 2024 37929813
13 Nocardiosis in Japan: a multicentric retrospective cohort study Antimicrob Agents Chemother Takamatsu A Yaguchi T Tagashira Y Watanabe A Honda H 0 66 2022
14 Primary cutaneous nocardiosis caused by a novel Nocardia species Br J Dermatol Zhuang K Ran Y 0 187 2022
15 Multiple brain abscesses caused by Nocardia asiatica: case report and literature review IDCases Jin S Guo X Xing H Li D Wang Y Ma W 0 34 2023
16 Cerebral abscess infected by Nocardia gipuzkoensis Infect Drug Resist Li X Feng Y Li D 7247 7253 16 2023 38023399
17 The first reported pulmonary nocardiosis caused by Nocardia gipuzkoensis resisted to trimethoprim/sulfamethoxazol (TMP-SMZ) in an immunocompetent patient J Glob Antimicrob Resist Duan Y Zhang X Deng W 214 218 37 2024 38462073
18 Identification and antimicrobial susceptibility profiles of Nocardia species clinically isolated in Japan Sci Rep Toyokawa M Ohana N Ueda A 16742 11 2021 34408177
19 Clinical characteristics, susceptibility profiles, and treatment of nocardiosis: a multicenter retrospective study in 2015-2021 Int J Infect Dis Yang J Ren HT Wang J 136 143 130 2023 36871785
20 Antibiotic susceptibility testing and species identification of Nocardia isolates: a retrospective analysis of data from a French expert laboratory, 2010-2015 Clin Microbiol Infect Lebeaux D Bergeron E Berthet J 489 495 25 2019 29933049
